Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Hypertension Clinical Trial

Official title:

A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan in Healthy Male Volunteer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01609907
• Other study ID #: YH14700-101
• Status: Completed
• Phase: Phase 1
• First received: January 5, 2012
• Last updated: May 31, 2012
• Start date: November 2011
• Est. completion date: May 2012

Study information

• Verified date: January 2012
• Source: Yuhan Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to compare pharmacokinetics after single oral administration of rosuvastatin and valsartan each separately versus coadministration of rosuvastatin and valsartan in healthy male volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy male volunteers of aged between 20 years to 50 years

• Have a body mass index (BMI) between 19kg/m2 and 27kg/m2 inclusive

• Eligible subjects with acceptable medical history, physical examination laboratory tests, ECG during screening period

• Able to follow instruction and can participate in whole procedure of the trial

• Have signed a written informed consent voluntary, prior to the any procedure, using a form that is approved by the local Institutional Review Board after detail explanation of the drug

• Anticipate having the same adult female sexual partner, who have no possibility of being pregnant or breast-feeding and take steps to prevent conception during the study

Exclusion Criteria:

• Have history of cardiovascular disorder(congestive heart failure, complications of coronary artery stenosis stroke and etc.), respiratory disorder, renal disorder(severe renal failure and etc.), liver disorder(moderate or severe liver failure and etc.) endocrine system disorder(diabetics, impaired glucose tolerance and etc.), digestive system disorder, central nervous system disorder, mental illness or malignant tumor

• Have history of gastrointestinal disease(Crohn's disease, ulcer and etc.), gastrointestinal surgery(simple appendectomy or herniotomy excluded) that can affect the absorption of the drug

• Have suffered from a clinically significant disease within 30 days prior to the first administration

• Have a known hypersensitivity or history of clinically significant hypersensitivity to drugs including the same class drugs with rosuvastatin or valsartan, or other drug(aspirin, antibiotics and etc.)

• Have genetic myopathy, family history of myopathy, or history of myopathy to drugs

• Have systolic blood pressure higher than 150mmHg or lower than 90mmHg, or diastolic blood pressure higher than 100mmHg or lower than 60mmHg, or pulse rate more than 100times/min or less than 40times/min

• Have history of drug abuse or shown positive on drug abuse during drug screening test

• Participated in any other clinical trials within 90 days prior to the first administration

• Have used any herbal medicine, prescription drug, or generic medicine within 30 days, 14 days or 7 days prior to the first administration, respectively (provided, however, if other conditions are judged to be eligible by investigators, subjects can participate in the trial)

• Donated whole blood or blood component within 60 days or 30 days prior to the first administration, respectively, or received transfusion within 30 days prior to the first administration

• Excessive alcohol drinker(> 140g/week; 1 glass of 12° wine(125mL) = 12.0g, 1 glass of 4° beer(250mL) = 8g, 0.5 bottle of soju(180mL) = 28.8g)

• Heavy smoker(> 20 cigarettes/day)

• Excessive caffeine drinker(> 4 cups/day)

• Shown positive on serum test(HBsAg, HCV Ab, HIV Ab tests)

• Subject who is judged to be ineligible by principal investigator or sub-investigator according to various reasons including their abnormal values in clinical laboratory test

• Continuous increase of liver enzyme level(AST, ALT) of unknown cause or active liver disorder patients with liver enzyme level increasing more than 3 time of normal upper limit

• Severe renal disorder patients(with creatinine clearance (Cr) < 10mL/min when calculated with Modification of Diet in Renal Disease method)

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hyperlipidemia
• Hyperlipidemias
• Hypertension

Intervention

Drug:
• Rosuvastatin+Valsartan (Sequence 1)
Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
• Rosuvastatin+Valsartan (Sequence 2)
Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
• Rosuvastatin+Valsartan (Sequence 3)
Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
• Rosuvastatin+Valsartan (Sequence 4)
Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
• Rosuvastatin+Valsartan (Sequence 5)
Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
• Rosuvastatin+Valsartan (Sequence 6)
Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

Locations

Country	Name	City	State
Korea, Republic of	Yuhan Corporation	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Yuhan Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax,ss of valsartan		18 points up to Day 4	No
Primary	AUCt,ss of valsartan		18 points up to Day 4	No
Primary	Cmax,ss of rosuvastatin		18 points up to Day 4	No
Primary	AUCt,ss of rosuvastatin		18 points up to Day 4	No
Primary	t1/2 of rosuvastatin		18 points up to Day 4	No
Secondary	Tmax,ss of valsartan		18 points up to Day 4	No
Secondary	t1/2 of valsartan		18 points up to Day 4	No
Secondary	Cmin,ss of valsartan		18 points up to Day 4	No
Secondary	Tmax,ss of rosuvastatin		18 points up to Day 4	No
Secondary	Cmin,ss of rosuvastatin		18 points up to Day 4	No
Secondary	t1/2 of rosuvastatin		18 points up to Day 4	No
Secondary	Cmax,ss of N-desmetyl rosuvastatin		18 points up to Day 4	No
Secondary	AUCt,ss of N-desmetyl rosuvastatin		18 points up to Day 4	No